| Literature DB >> 32454800 |
M Ardiana1,2, B S Pikir2, A Santoso3, H O Hermawan4, M J Al-Farabi1,5.
Abstract
INTRODUCTION: Nigella sativa is a commonly used traditional medicine which has been shown to have antioxidant properties. However, its supplementation in patients of clinical trials showed conflicting results. Materials and Method. Relevant articles were searched through PubMed/Medline, SCOPUS, and Google Scholar databases using "Nigella sativa" or "black seed" or "black caraway" or "thymoquinone" and "oxidative stress" or "antioxidant" and "clinical trial" keywords. Randomized, placebo-controlled human interventions using Nigella sativa were included in this study. The methodological quality of studies was assessed using Jadad's quality scales.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32454800 PMCID: PMC7225850 DOI: 10.1155/2020/2390706
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Figure 1Flow diagram of the number of studies included in the meta-analysis.
Characteristics of the included studies.
| Author | Year | Study design | Target population | NS form | Dose/day | Duration | Gender | Age | Sample size | Outcome | Jadad score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hadi et al. [ | 2018 | Randomized, double-blind, placebo-controlled trial | DM type 2 | Oil capsule | 500 mg | 8 weeks | Female | 30–60 | 43 | MDA, SOD, TNF- | 3 |
|
| |||||||||||
| Hadi et al. [ | 2016 | Randomized, double-blind, placebo-controlled trial | Rheumatoid arthritis | Oil capsule | 500 mg | 8 weeks | Female | 20–50 | 39 | MDA, TAC, SOD, TNF- | 4 |
|
| |||||||||||
| Kaatabi et al. [ | 2015 | Randomized, participant blind, placebo-controlled trial | DM type 2 | Powder capsule | 2 gr | 48 weeks | Both | 18–60 | 114 | TAC, SOD, FBG, HbA1c, C-peptide, insulin resistance, beta-cell activity, CAT, glutathione, TBARS | 3 |
|
| |||||||||||
| Nikkhah-Bodaghi et al. [ | 2019 | Randomized, double-blind, placebo-controlled trial | Ulcerative colitis | Powder capsule | 500 mg | 6 weeks | Both | >18 | 48 | MDA, TAC, TNF- | 4 |
|
| |||||||||||
| Namazi et al. [ | 2015 | Randomized, double-blind, placebo-controlled trial | Obese | Oil capsule | 3 gr | 8 weeks | Female | 25–50 | 49 | MDA, TAC, SOD, GPx | 4 |
Figure 2Forest plot displaying weighted mean difference and 95% confidence intervals for the impact of NS supplementation on MDA.
Figure 3Forest plot displaying weighted mean difference and 95% confidence intervals for the impact of NS supplementation on SOD.
Figure 4Forest plot displaying weighted mean difference and 95% confidence intervals for the impact of NS supplementation on TAC.